Latest Product Pipeline News

XReality Group (ASX:XRG) posts strong FY26 revenue and ARR growth, marking key milestones with its first commercial MR-1 mixed reality sale to the US Department of Defense and debut European contract with the Swedish Armed Forces.

CleanSpace Holdings expects modest revenue growth for FY26, hindered by product certification delays and global market challenges, while maintaining a strong cash position and preparing a new respirator launch.

Pacific Edge reported a steep 47% revenue drop in FY26 following Medicare coverage loss but secured a draft Medicare policy covering its Cxbladder tests and raised NZ$25.4 million to fuel growth and commercial execution.

BCAL Diagnostics has embedded referral forms for its early cancer detection tests into clinical software used by 97% of Australian GPs, launched a telehealth platform, and opened a Sydney clinic, gearing up for a multi-cancer test launch in June 2026.

5E Advanced Materials secures a decade-long boric acid offtake agreement and advances boron product development, while reporting a $12.1 million quarterly loss and planning ASX delisting.

Catalyst Metals continues to expand the Trident underground gold deposit with drilling results that extend mineralisation beyond current resources, underpinning a decade-long mine plan at 60,000 ounces per annum.

Great Boulder Resources has raised $40 million through a two-tranche placement to fund its acquisition of Westgold’s Peak Hill Gold Project, positioning the company for an aggressive drilling campaign and a pathway to capital light production.

Optiscan Imaging has submitted its FDA dossier for InSpecta®, marking a crucial step toward US veterinary market entry, while progressing clinical studies for InVue® and InForm® ahead of further FDA submissions in 2026.

One Click Group delivered a remarkable 1000% increase in new users and a 64% reduction in acquisition costs in Q1 2026, setting the stage for strong revenue growth ahead of tax season.

Osteopore Limited posted a 10% quarter-on-quarter revenue increase to AUD 754K in Q1 CY26, driven by new distribution deals across China, Latin America, and Hong Kong, alongside launching 3D printing services and securing innovative bone graft technologies in Asia Pacific.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

ECS Botanics reports a third straight quarter of positive operating cash flow, driven by strong B2C growth and strategic international shipments to Germany and New Zealand.